Time Course of Early Hematoma Expansion in Acute Spot-Sign Positive Intracerebral Hemorrhage: Prespecified Analysis of the SPOTLIGHT Randomized Clinical Trial

Author:

Al-Ajlan Fahad S.1ORCID,Gladstone David J.23,Song Dongbeom4,Thorpe Kevin E.5ORCID,Swartz Rick H.23,Butcher Kenneth S.6ORCID,del Campo Martin3,Dowlatshahi Dar7ORCID,Gensicke Henrik8ORCID,Lee Gloria Jooyoung4,Flaherty Matthew L.9ORCID,Hill Michael D.4ORCID,Aviv Richard I.9ORCID,Demchuk Andrew M.4ORCID,Swartz Richard H.,Gladstone David J.,Boyle Karl,Braganza Maria,Fedasko Nadia,Golob Dolores,Bardi Edith,Senyshyn Samantha,Cayley Megan,Colavecchia Connie,Demchuk Andrew M.,Hill Michael D.,Coutts Shelagh,Klein Gary,Menon Bijoy,Watson Tim,Smith Eric,Subramaniam Suresh,Bal Simerpreet,Barber Philip,Camden Marie-Christine,Horton Myles,Mishra Sachin,Nambiar Vivek,Torres Andres Venegas,Adatia Sweta,Alseraya Amjad,Desai Jamsheed,Mandzia Jennifer,Shamy Michel,Trivedi Anurag,Choi Philip,Dubuc Veronique,Klourfeld Evgenia,Field Thalia,Singh Dilip,Musuka Tapuwa,Bloujney Sarah,Nikneshan Davar,Imoukhuede Oje,Yu Amy,Appireddy Ramana,Evans Jamie,Ryckborst Karla,Calvert Carly,Dowlatshahi Dariush,Stotts Grant,Sharma Mukul,Robert Sohail,Mortensen Melodie,Shamloul Rany,Campo Martin Del,Silver Frank L.,Casaubon Leanne,Jaigobin Cheryl,Perez Yael,Kalman Libby,Abraham Jemini,Wiegner Relu,Cayley Anne,Riediger Victoria,Butcher Ken,Kate Mahesh,Jeerakathil Thomas,Shuaib Ashfaq,Gaucher Sylvia,Sivakumar Leka,Yip Samuel,Teal Philip,Woolfenden Andrew,Benavente Oscar,Beckman Jeff,Murphy Colleen,Field Thalia,Asdaghi Negar,Villaluna-MurrVay Karina,Sahlas Demetrios J.,Algird Almunder,Knapman Jordan,Macmillan Sue,Sancan Janice,Mehdiratta Manu,Perez Yael,John Verity,Dhanani AlNoor,Temple Bryan,Douen Andre,Selchen Daniel,Saposnik Gustavo,Kostyrko Pawel,Chan Richard,Young Bryan,Kumar Balagopal,Soros Peter,Hesser Kimberley,Wright Mary,Frank Connie,Amato-Marziali Belinda,Deschaintre Yan,Poppe Alexandre,Lapierre Marlene,Boulanger Jean-Martin,Berger Leo,Blais Lise,Simard Christel,Teitelbaum Jeanne,Campbell Natasha,Jin Al,Breen Adriana,Bickford Suzanne

Affiliation:

1. Department of Neurosciences (Neurology), King Faisal Specialist Hospital and Research Center, Alfaisal University, Riyadh, Saudi Arabia (F.S.A.-A.).

2. Sunnybrook Research Institute, Hurvitz Brain Sciences Program and Department of Medicine, Sunnybrook Health Sciences Centre (D.J.G., R.H.S.)

3. Department of Medicine (Neurology), University of Toronto, Canada (D.J.G., R.H.S., M.D.C.).

4. Calgary Stroke Program, Department of Clinical Neurosciences, Department of Radiology, Hotchkiss Brain Institute, Cumming School of Medicine, University of Calgary, Canada (D.S., G.J.L., M.D.H., A.M.D.).

5. Applied Health Research Centre, Li Ka Shing Knowledge Institute, St. Michael’s Hospital, Dalla Lana School of Public Health, University of Toronto, Canada (K.E.T.).

6. Prince of Wales Clinical School, University of New South Wales, Sydney, AustraliaDepartment of Medicine (Neurology), University of Alberta, Edmonton, Canada (K.S.B.).

7. Department of Medicine (Neurology), University of Ottawa and Ottawa Hospital Research Institute, Canada (D.D.).

8. Stroke Center and Neurology, University Hospital Basel, Switzerland (H.G.).

9. Department of Neurology, University of Cincinnati, OH (M.L.F., R.I.A.). Division of Neuroradiology and Department of Medical Imaging, Sunnybrook Health Sciences Centre, University of Toronto, Canada.

Abstract

Background: In the SPOTLIGHT trial (Spot Sign Selection of Intracerebral Hemorrhage to Guide Hemostatic Therapy), patients with a computed tomography (CT) angiography spot-sign positive acute intracerebral hemorrhage were randomized to rFVIIa (recombinant activated factor VIIa; 80 μg/kg) or placebo within 6 hours of onset, aiming to limit hematoma expansion. Administration of rFVIIa did not significantly reduce hematoma expansion. In this prespecified analysis, we aimed to investigate the impact of delays from baseline imaging to study drug administration on hematoma expansion. Methods: Hematoma volumes were measured on the baseline CT, early post-dose CT, and 24 hours CT scans. Total hematoma volume (intracerebral hemorrhage+intraventricular hemorrhage) change between the 3 scans was calculated as an estimate of how much hematoma expansion occurred before and after studying drug administration. Results: Of the 50 patients included in the trial, 44 had an early post-dose CT scan. Median time (interquartile range) from onset to baseline CT was 1.4 hours (1.2–2.6). Median time from baseline CT to study drug was 62.5 (55–80) minutes, and from study drug to early post-dose CT was 19 (14.5–30) minutes. Median (interquartile range) total hematoma volume increased from baseline CT to early post-dose CT by 10.0 mL (−0.7 to 18.5) in the rFVIIa arm and 5.4 mL (1.8–8.3) in the placebo arm ( P =0.96). Median volume change between the early post-dose CT and follow-up scan was 0.6 mL (−2.6 to 8.3) in the rFVIIa arm and 0.7 mL (−1.6 to 2.1) in the placebo arm ( P =0.98). Total hematoma volume decreased between the early post-dose CT and 24-hour scan in 44.2% of cases (rFVIIa 38.9% and placebo 48%). The adjusted hematoma growth in volume immediately post dose for FVIIa was 0.998 times that of placebo ([95% CI, 0.71–1.43]; P =0.99). The hourly growth in FFVIIa was 0.998 times that for placebo ([95% CI, 0.994–1.003]; P =0.50; Table 3). Conclusions: In the SPOTLIGHT trial, the adjusted hematoma volume growth was not associated with Factor VIIa treatment. Most hematoma expansion occurred between the baseline CT and the early post-dose CT, limiting any potential treatment effect of hemostatic therapy. Future hemostatic trials must treat intracerebral hemorrhage patients earlier from onset, with minimal delay between baseline CT and drug administration. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT01359202.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Advanced and Specialized Nursing,Cardiology and Cardiovascular Medicine,Neurology (clinical)

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3